Abstract
Moderate exercise is an effective and economic way to prevent and treat cardiovascular diseases. Unlike pathological cardiac growth, exercise-induced cardiac growth, excluding extreme strenuous exercise, does not cause cardiac cell death, fibrosis, and cardiac dysfunction. The balanced cardiomyogenesis (cardiomyocyte hypertrophy and hyperplasia) and neo-angiogenesis are essential determinants for exercise-induced cardiac growth. In particular, exercise leads to physiological cardiac growth through regulating the IGF-1-PI3K-Akt, nitric oxide (NO), C/EBPβ, and PGC-1α signaling pathways, which might be novel therapeutic targets for cardiac diseases. The formation of new cardiomyocytes in response to exercise suggests that exercise might be a useful tool to enhance cardiac regenerative capacity. Exercise also exerts its protective effects against cardiac aging and cardiac metabolic derangement. Moreover, growing evidence reveals the regulation of cardiac and circulating microRNAs in response to exercise. A better understanding of the mechanisms underlying exercise-induced cardioprotection will lead to the development of innovative pharmacotherapies for cardiac diseases.
Keywords: Exercise, cardiac growth, regeneration, aging, metabolism, microRNA.
Current Pharmaceutical Design
Title:Exercise as a platform for pharmacotherapy development in cardiac diseases
Volume: 21 Issue: 30
Author(s): Yihua Bei, Qiulian Zhou, Qi Sun and Junjie Xiao
Affiliation:
Keywords: Exercise, cardiac growth, regeneration, aging, metabolism, microRNA.
Abstract: Moderate exercise is an effective and economic way to prevent and treat cardiovascular diseases. Unlike pathological cardiac growth, exercise-induced cardiac growth, excluding extreme strenuous exercise, does not cause cardiac cell death, fibrosis, and cardiac dysfunction. The balanced cardiomyogenesis (cardiomyocyte hypertrophy and hyperplasia) and neo-angiogenesis are essential determinants for exercise-induced cardiac growth. In particular, exercise leads to physiological cardiac growth through regulating the IGF-1-PI3K-Akt, nitric oxide (NO), C/EBPβ, and PGC-1α signaling pathways, which might be novel therapeutic targets for cardiac diseases. The formation of new cardiomyocytes in response to exercise suggests that exercise might be a useful tool to enhance cardiac regenerative capacity. Exercise also exerts its protective effects against cardiac aging and cardiac metabolic derangement. Moreover, growing evidence reveals the regulation of cardiac and circulating microRNAs in response to exercise. A better understanding of the mechanisms underlying exercise-induced cardioprotection will lead to the development of innovative pharmacotherapies for cardiac diseases.
Export Options
About this article
Cite this article as:
Bei Yihua, Zhou Qiulian, Sun Qi and Xiao Junjie, Exercise as a platform for pharmacotherapy development in cardiac diseases, Current Pharmaceutical Design 2015; 21 (30) . https://dx.doi.org/10.2174/1381612821666150803150008
DOI https://dx.doi.org/10.2174/1381612821666150803150008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds
Mini-Reviews in Medicinal Chemistry Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Hydrogels: A Journey from Diapers to Gene Delivery
Mini-Reviews in Medicinal Chemistry GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Patent Selections
Recent Patents on Medical Imaging Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry MicroRNA in Aging: From Discovery to Biology
Current Genomics Urocortins: Putative Role in Cardiovascular Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets “Seeing is Believing”: Perspectives of Applying Imaging Technology in Discovery Toxicology
Combinatorial Chemistry & High Throughput Screening Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design